Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KERNNYSE:NAVBNASDAQ:NHNASDAQ:NHIQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKERNAkerna$5.89$0.17▼$6.40$64.92M3.02339,022 shs70,795 shsNAVBNavidea Biopharmaceuticals$0.00$0.00$0.00▼$0.13$20K1.78,490 shs820 shsNHNantHealth$0.01$0.01$1.24▼$9.75$77K1.8238,073 shsN/ANHIQNantHealth$0.01$0.01$0.00▼$1.60$326K-5.84478 shs1 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKERNAkerna0.00%0.00%0.00%0.00%0.00%NAVBNavidea Biopharmaceuticals0.00%0.00%-71.43%-50.00%0.00%NHNantHealth0.00%+222.58%+222.58%+376.19%-98.33%NHIQNantHealth0.00%0.00%+222.58%+376.19%-66.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKERNAkernaN/AN/AN/AN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANHNantHealthN/AN/AN/AN/AN/AN/AN/AN/ANHIQNantHealthN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKERNAkerna 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/ANHNantHealth 0.00N/AN/AN/ANHIQNantHealth 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKERNAkerna$13.65M0.00N/AN/A($1.52) per share0.00NAVBNavidea Biopharmaceuticals$8.13K2.46N/AN/AN/A∞NHNantHealth$67.68M0.00N/AN/A($30.72) per share0.00NHIQNantHealth$67M0.00N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKERNAkerna-$79.06M-$7.10N/AN/AN/A-339.99%N/A-113.03%N/ANAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/ANHNantHealth-$67.78M-$7.65N/A∞N/A-94.67%N/A-39.82%N/ANHIQNantHealth-$67.78MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKERNAkernaN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/ANHNantHealthN/AN/AN/AN/AN/ANHIQNantHealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKERNAkernaN/A0.100.10NAVBNavidea BiopharmaceuticalsN/AN/AN/ANHNantHealthN/A0.640.64NHIQNantHealthN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKERNAkerna21.97%NAVBNavidea Biopharmaceuticals0.01%NHNantHealth4.50%NHIQNantHealthN/AInsider OwnershipCompanyInsider OwnershipKERNAkerna1.20%NAVBNavidea Biopharmaceuticals43.68%NHNantHealth61.30%NHIQNantHealth61.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKERNAkerna11210.35 million10.23 millionNo DataNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableNHNantHealth3407.70 million2.98 millionNot OptionableNHIQNantHealth34032.60 million12.62 millionNot OptionableNH, NHIQ, KERN, and NAVB HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comTop HeadlinesView All Headlines3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsLululemon, UNH, Enphase: Bad News, Good Opportunity?By Thomas Hughes | June 17, 2025View Lululemon, UNH, Enphase: Bad News, Good Opportunity?3 Oversold Stocks Flashing Bullish Reversal SignalsBy Sam Quirke | June 7, 2025View 3 Oversold Stocks Flashing Bullish Reversal SignalsRobinhood Drops on S&P Snub—Is a Bigger Pullback Coming?By Chris Markoch | June 10, 2025View Robinhood Drops on S&P Snub—Is a Bigger Pullback Coming?Robinhood Stock Keeps Giving Investors Reasons To BuyBy Gabriel Osorio-Mazilli | June 4, 2025View Robinhood Stock Keeps Giving Investors Reasons To BuyNH, NHIQ, KERN, and NAVB Company DescriptionsAkerna NASDAQ:KERNAkerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.Navidea Biopharmaceuticals NYSE:NAVB$0.0002 0.00 (0.00%) As of 06/26/2025 01:22 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.NantHealth NASDAQ:NH$0.01 0.00 (0.00%) As of 06/25/2025NantHealth, Inc. engages in the provision of enterprise solutions that help businesses transform complex data into actionable insights. It is also involved in marketing solutions as a comprehensive integrated solution that includes clinical decision support, payer engagement solutions, data analysis, and network monitoring and management. The company was founded by Patrick Soon-Shiong on July 7, 2010 and is headquartered in Morrisville, NC.NantHealth NASDAQ:NHIQ$0.01 0.00 (0.00%) As of 06/24/2025NantHealth, Inc., together with its subsidiaries, operates as a healthcare IT company in the United States, Canada, and the United Kingdom. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans, and centers for medicare and medicaid services for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers Quadris, a data solution that includes multi-data analysis, reporting, and professional services. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was incorporated in 2010 and is headquartered in Morrisville, North Carolina. NantHealth, Inc. is a subsidiary of NantWorks, LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
